EE05233B1 - (R)-ibuprofeenmetaansulfoonamiidi v?i selle soola kasutamine ravimite valmistamiseks, mis on ette n„htud siiratud elundite isheemia/reperfusiooni kahjustuse „rahoidmiseks v?i raviks - Google Patents

(R)-ibuprofeenmetaansulfoonamiidi v?i selle soola kasutamine ravimite valmistamiseks, mis on ette n„htud siiratud elundite isheemia/reperfusiooni kahjustuse „rahoidmiseks v?i raviks

Info

Publication number
EE05233B1
EE05233B1 EEP200300340A EEP200300340A EE05233B1 EE 05233 B1 EE05233 B1 EE 05233B1 EE P200300340 A EEP200300340 A EE P200300340A EE P200300340 A EEP200300340 A EE P200300340A EE 05233 B1 EE05233 B1 EE 05233B1
Authority
EE
Estonia
Prior art keywords
treatment
salt
financing
ischemia
medicament
Prior art date
Application number
EEP200300340A
Other languages
English (en)
Estonian (et)
Inventor
Bertini Riccardo
Colotta Francesco
Novellini Roberto
Original Assignee
Domp S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domp S.P.A. filed Critical Domp S.P.A.
Publication of EE200300340A publication Critical patent/EE200300340A/xx
Publication of EE05233B1 publication Critical patent/EE05233B1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
EEP200300340A 2001-02-02 2002-01-30 (R)-ibuprofeenmetaansulfoonamiidi v?i selle soola kasutamine ravimite valmistamiseks, mis on ette n„htud siiratud elundite isheemia/reperfusiooni kahjustuse „rahoidmiseks v?i raviks EE05233B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI000206A ITMI20010206A1 (it) 2001-02-02 2001-02-02 Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
PCT/EP2002/000946 WO2002062330A2 (fr) 2001-02-02 2002-01-30 Utilisation de (r)-ibuprofene methane sulfonamide et de ses sels pour le traitement et la prevention des reactions de rejet a la suite de transplantations d'organes

Publications (2)

Publication Number Publication Date
EE200300340A EE200300340A (et) 2003-10-15
EE05233B1 true EE05233B1 (et) 2009-12-15

Family

ID=11446717

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300340A EE05233B1 (et) 2001-02-02 2002-01-30 (R)-ibuprofeenmetaansulfoonamiidi v?i selle soola kasutamine ravimite valmistamiseks, mis on ette n„htud siiratud elundite isheemia/reperfusiooni kahjustuse „rahoidmiseks v?i raviks

Country Status (26)

Country Link
US (1) US7560487B2 (fr)
EP (1) EP1355641B1 (fr)
JP (1) JP2004517948A (fr)
KR (1) KR100857898B1 (fr)
CN (1) CN1561205A (fr)
AT (1) ATE304846T1 (fr)
AU (1) AU2002250869B2 (fr)
BR (2) BR0206804A (fr)
CA (1) CA2432432C (fr)
CZ (1) CZ303665B6 (fr)
DE (1) DE60206245T2 (fr)
DK (1) DK1355641T3 (fr)
EE (1) EE05233B1 (fr)
ES (1) ES2248541T3 (fr)
HU (1) HU229070B1 (fr)
IL (1) IL157180A (fr)
IT (1) ITMI20010206A1 (fr)
MX (1) MXPA03006686A (fr)
NO (1) NO334285B1 (fr)
NZ (1) NZ526655A (fr)
PL (1) PL215109B1 (fr)
PT (1) PT1355641E (fr)
RU (1) RU2257895C2 (fr)
SK (1) SK287632B6 (fr)
WO (1) WO2002062330A2 (fr)
ZA (1) ZA200304861B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1579859T1 (sl) * 2004-03-25 2007-04-30 Dompe Pha R Ma Spa Res & Mfg Uporaba n-(2-aril-propionil)-sulfonamidov za zdravljenje poskodbe hrbtnega mozga
JP2008545627A (ja) 2005-05-09 2008-12-18 タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド 腎結石症を治療する方法
CN101677999A (zh) * 2006-11-13 2010-03-24 塔普医药产品公司 使用黄嘌呤氧化还原酶抑制剂保护肾功能的方法
EP2308485A1 (fr) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides pour la prévention du diabète
EP2308484A1 (fr) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibiteurs de cxcr1/2 en tant qu'adjuvants pour la transplantation d'îlets pancréatiques
WO2012033941A1 (fr) 2010-09-10 2012-03-15 Takeda Pharmaceuticals North America, Inc. Méthodes de traitement simultané à base de théophylline et de fébuxostat
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
CA3055004C (fr) * 2017-03-15 2023-10-03 Numares Ag Utilisation d'un ensemble de marqueurs pour determiner le risque de rejet de rein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879283A (en) * 1985-10-03 1989-11-07 Wisconsin Alumni Research Foundation Solution for the preservation of organs
JPH08231413A (ja) * 1994-12-29 1996-09-10 Mochida Pharmaceut Co Ltd 臓器障害に基づく疾患の予防・治療剤
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
US6355682B1 (en) * 2001-05-11 2002-03-12 Assa Weinberg Treatment of acute renal failure by administration of N-acetylcysteine

Also Published As

Publication number Publication date
PL215109B1 (pl) 2013-10-31
NO334285B1 (no) 2014-01-27
NO20033273L (no) 2003-07-18
DE60206245D1 (de) 2006-02-02
KR20030074725A (ko) 2003-09-19
PT1355641E (pt) 2005-11-30
CA2432432A1 (fr) 2002-08-15
NO20033273D0 (no) 2003-07-18
ZA200304861B (en) 2004-06-30
AU2002250869B2 (en) 2006-10-19
SK287632B6 (sk) 2011-04-05
WO2002062330A3 (fr) 2003-04-03
US20040102520A1 (en) 2004-05-27
HU229070B1 (hu) 2013-07-29
DK1355641T3 (da) 2005-10-17
WO2002062330A2 (fr) 2002-08-15
NZ526655A (en) 2005-02-25
KR100857898B1 (ko) 2008-09-10
ATE304846T1 (de) 2005-10-15
US7560487B2 (en) 2009-07-14
HUP0303024A3 (en) 2005-07-28
RU2003126600A (ru) 2005-02-27
EP1355641A2 (fr) 2003-10-29
ES2248541T3 (es) 2006-03-16
CZ303665B6 (cs) 2013-02-20
BRPI0206804B1 (pt) 2018-09-25
MXPA03006686A (es) 2004-05-31
EP1355641B1 (fr) 2005-09-21
EE200300340A (et) 2003-10-15
DE60206245T2 (de) 2006-06-14
CZ20032095A3 (en) 2004-05-12
JP2004517948A (ja) 2004-06-17
SK9732003A3 (en) 2003-11-04
ITMI20010206A1 (it) 2002-08-02
HUP0303024A2 (hu) 2003-12-29
BR0206804A (pt) 2004-02-03
CN1561205A (zh) 2005-01-05
IL157180A (en) 2009-06-15
CA2432432C (fr) 2008-03-25
RU2257895C2 (ru) 2005-08-10
PL363576A1 (en) 2004-11-29

Similar Documents

Publication Publication Date Title
ATE517624T1 (de) Behandlung von neurodegenerativen erkrankungen und krebs im gehirn
EE02971B1 (et) Droloksüfeeni või selle soolade kasutamine luuhaiguste vastase ravimi valmistamiseks
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
DK1235826T3 (da) Quinuclidinacrylamider
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
CA2436462A1 (fr) Inhibiteurs de la cruzipaine et autres cysteines proteases
EE05233B1 (et) (R)-ibuprofeenmetaansulfoonamiidi v?i selle soola kasutamine ravimite valmistamiseks, mis on ette n„htud siiratud elundite isheemia/reperfusiooni kahjustuse „rahoidmiseks v?i raviks
EP1197210A4 (fr) Agents inhibant les reactions de rejet chronique faisant suite a une greffe d'organe
BR0113062A (pt) Derivados de heterociclilalquilazol e seu emprego como agente para o combate de parasitas
ATE521344T1 (de) Calciumsalze zur behandlung von psoriasis, dermatitis und schuppen
TR200200473T2 (tr) Rar selektif retinoid agonistleri.
BR0313655A (pt) Uso de n-(3-metóxi-5-metilpirazin-2-il)-2-(4-[1, 3, 4-oxadiazol-2-il]fenil) piridina-3-sulfonamida, ou um sal do mesmo farmaceuticamente aceitável
NO20052562L (no) Anvendelse av distrontiumsalter av 2-[N,N-di(karboksylmetyl)amino]-3-cyano-4-karboksylmetyl-tiofen-5-karboksylsyre for fremstilling av medikamenter for behandlingen av gastro-duodenal smerte.
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
JP2004517948A5 (fr)
DE602004022783D1 (de) Heterozyklische harnstoff-derivate für die behandlung von schmerzen.
SE0300535D0 (sv) Treatment of burns
RU2004119059A (ru) Препарат для лечения и профилактики эндометритов у коров - "альгацин"
DK1755583T3 (da) Anvendelse af neboglamin til behandling af skizofreni
PL1514545T3 (pl) Zastosowanie tolperyzonu do leczenia skurczów narządów zbudowanych zasadniczo z mięśni gładkich
TH57870B (th) การใช้แบบใหม่ของสารประกอบในฐานะสารต้านแบคทีเรีย
BR0307468A (pt) Derivados tiadiazinona antimicrobianos úteis no tratamento de infecções bacterianas
RU2006104187A (ru) Препарат для лечения микозов и гнойной инфекции
EA200501765A2 (ru) Средство для лечения болезней суставов
RU2003117875A (ru) Фармацевтическая композиция для лечения воспалительных процессов заднего отрезка глаза "кселипос"

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20101231

GB1A Change in the ownership or in the address of the owner
MM4A Lapsed by not paying the annual fees

Effective date: 20200130